Background: The American Thoracic Society convened an international multidisciplinary
panel to develop clinical practice guidelines for the treatment of systemic sclerosis …

Background: The American Thoracic Society convened an international, multidisciplinary
panel to develop clinical practice guidelines for the treatment of systemic sclerosis …

Background: Interstitial lung disease (ILD) is a significant cause of morbidity and mortality in
patients with systemic sclerosis (SSc). To date, clinical practice guidelines regarding …

Systemic sclerosis (SSc), or scleroderma, is a rare, complex, systemic autoimmune disease
of unknown aetiology, characterized by high morbidity and mortality often resulting from …

Background: The American Thoracic Society (ATS) convened an international,
multidisciplinary panel to develop clinical practice guidelines for the treatment of systemic …

Cyclophosphamide (CYC) has been a gold standard of treatment for severe progressive
Systemic Sclerosis (SSc), especially in patients with concomitant interstitial lung disease …

Background When research evidence is limited, inconsistent, or absent, healthcare
decisions and policies need to be based on consensus among interested stakeholders. In …

Background Pulmonary arterial hypertension (PAH) and interstitial lung disease (ILD) are
leading causes of systemic sclerosis (SSc)-related death. In this study, we aimed to identify …

Systemic sclerosis (SSc) is a heterogeneous autoimmune disease, where a significant
proportion of patients develop interstitial lung disease (ILD), which is the major cause of …

Introduction Interstitial lung disease (ILD) is the leading cause of mortality in patients with
systemic sclerosis (SSc). Risk of developing progressive ILD is highest among patients with …